Skip to main content
. 2017 Nov 9;3(4):622–635. doi: 10.1016/j.trci.2017.10.001

Table 2.

Summary of adverse events in the double-blind phase

Adverse events Placebo group (n = 15) PBT2 group (n = 27, includes 2 withdrawals)
One of more AE 15 26
Related AE 10 23
Serious AE 4 3
Death 0 1
Nature of AE reported by ≥ 2 participants
 Cardiac 2 1
 Ear 2 0
 Eye 5 10
 Gastrointestinal 8 7
 General 0 5
 Immune system 1 3
 Infection 11 14
 Injury 1 2
 Investigational 1 4
 Metabolic 3 2
 Musculoskeletal 4 6
 Neoplasia 0 2
 Nervous system 6 17
 Respiratory 1 4
 Skin 2 8

Abbreviation: AE, adverse event.